IMPACT Therapeutics, Inc. Class H

As of June 30, 2026, IMPACT Therapeutics, Inc. Class H carries a market capitalization of 10.19B, placing it among publicly traded companies globally. Its enterprise value stands at 8.96B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

IMPACT Therapeutics, Inc. Class H's next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2026, IMPACT Therapeutics, Inc. Class H has 282.46M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, IMPACT Therapeutics, Inc. Class H maintains a current ratio of 8.06, meaning it holds 8.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

These figures are as of the close on October 22, 2026.

As of June 30, 2026, IMPACT Therapeutics, Inc. Class H holds 1.23B in cash and equivalents against 4.89M in total debt, resulting in a net debt position of -948.38M. Total book value stands at 896.62M, with working capital of 1.16B providing operational flexibility.